Is there a difference in the analgesic response to intra-articular bupivacaine injection in people with knee osteoarthritis pain with or without central sensitisation? Protocol of a feasibility randomised controlled trial

Yasmine Zedan,1,2,3 Roger Knaggs,4 Dale Cooper,5 Thomas Kurien,2,6 David Andrew Walsh,2,7 Dorothee P Auer,1,2,3 Brigitte E Scammell2,6

ABSTRACT

Introduction Pain is the main symptom of osteoarthritis (OA) with approximately 50% of patients reporting moderate-to-severe pain. Total knee replacement (TKR) is the ultimate treatment option to alleviate pain in knee OA. Nevertheless, TKR does not provide complete relief for all as approximately 20% of patients experience chronic postoperative pain. Painful peripheral stimuli may alter the central nociceptive pathways leading to central sensitisation that can influence treatment response in patients with OA. Currently, there is no objective protocol for detecting whether a patient will respond to a given treatment. Therefore, there is a need for a better mechanistic understanding of individual factors affecting pain relief, consequently informing personalised treatment guidelines. The purpose of this research is to examine the feasibility of conducting a full-scale mechanistic clinical trial in painful knee OA investigating the analgesic response to intra-articular bupivacaine between those with or without evidence of central sensitisation.

Methods and analysis The Understanding Pain mechanisms in KNEE osteoarthritis (UP-KNEE) study is a feasibility, double-blinded, placebo-controlled randomised parallel study in participants with radiographically defined knee OA and with self-reported chronic knee pain. The study involves the following assessments: (1) a suite of psychometric questionnaires; (2) quantitative sensory testing; (3) magnetic resonance imaging (MRI) scan of the knee and brain; (4) a 6-minute walk test; and (5) an intra-articular injection of bupivacaine or placebo (sodium chloride 0.9%) into the index knee. Assessments will be repeated post intra-articular injection apart from the MRI scan of the knee. Our aim is to provide proof of concept and descriptive statistics to power a future mechanistic trial.

Ethics and dissemination Ethical approval was obtained from the Health Research Authority (HRA) (REC: 20/EM/0287). Results will be disseminated via peer-reviewed journals and scientific conferences. The results will also be shared with lay audiences through relevant channels, such as Pain Centre Versus Arthritis website and patient advocacy groups.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ The study attempts to address a knowledge gap by providing mechanistic understanding of the factors contributing to the individual pain relief in knee osteoarthritis.
⇒ The feasibility design will support a future main trial.
⇒ Patients were involved in the development of the study protocol. They helped to identify the most relevant outcome measures, which were reordered to prioritise the patients’ preferences.
⇒ Owing to the nature of the feasibility study, no formal hypothesis testing will be performed in this trial. It will provide descriptive statistics which will inform the design and sample size requirements of a future definitive mechanistic trial.

Trial registration number NCT05561010.

INTRODUCTION

Rationale

Knee osteoarthritis (OA) is a leading cause of pain, functional disability and is a substantial economic burden on society and healthcare systems.1–3 Treatment guidelines for chronic knee pain in OA are mainly focused on pain management with a combination of pharmacological and non-pharmacological treatment approaches, but no disease-modifying treatment currently exists.4 Total knee replacement (TKR) is the ultimate treatment to alleviate pain, nevertheless chronic pain is still reported in about 20% of patients after the surgery.5 Currently, there is no objective protocol to detect how a patient will respond to a given OA treatment. Moreover, there is also a poor correlation between the severity
of joint damage and severity of pain, which points to the contribution of central pain mechanisms.

Painful peripheral stimuli may alter the central nociceptive pathways leading to central sensitisation that can influence treatment response in patients with OA. Sensitisation, which plays a key role in augmenting OA pain, is defined as a modified perception of pain due to increased impulses from the peripheral nervous system (peripheral sensitisation) along with augmentation of pain signals in the central nervous system (central sensitisation). Central sensitisation was estimated to be present in about 30% of patients with OA and was found to be a predictor for developing chronic postoperative pain after TKR.

Validated proxies, including questionnaires, neuroimaging and quantitative sensory testing (QST), have been used to examine pain sensitisation. However, a gold standard to diagnose pain sensitisation in a clinical setting is lacking, and individualised mechanism-based treatment in knee OA remains a pressing need.

### Evidence gap

Given the necessity for better understanding of the mechanisms of pain relief in knee OA, the purpose of this research is to examine the feasibility of conducting a full-scale mechanistic clinical trial investigating the analgesic response in knee OA between those with or without evidence of central sensitisation. The use of intra-articular bupivacaine, as an experimental medicine approach, has been shown to significantly reduce knee pain 1 hour after injection in previous studies; as it temporarily blocks peripheral pain stimuli, thereby potentially unmasking central pain components. Given that peripheral input commonly triggers central sensitisation, the theory that local anaesthesia will assist in differentiating patients with centrally mediated pain mechanisms is also supported by the notion that regional anaesthesia or local anaesthesia can reduce the risk of persistent postoperative pain 6 months after surgery according to a previous systematic review and meta-analysis. Additionally, the use of comprehensive pain phenotyping tools including MRI of the knee and brain will enable a better mechanistic understanding of individual factors affecting pain relief, consequently informing future personalised treatment guidelines.

### Objectives

- The primary objective of the UP-KNEE study is to evaluate the feasibility of a main definitive trial by: collecting data to inform sample size calculation; testing the recruitment process; Timing of the outcome measures; Testing the robustness of randomisation; Testing the integrity of the research protocol; and qualitative assessment of the acceptability of the methods of the feasibility study.
- The secondary objective of the study is to explore correlations of the analgesic response with indicators of central and peripheral pain mechanisms derived from MRI of the brain and knee, questionnaires and QST.

### Hypothesis

For the future main trial, the hypothesis is that the analgesic response to a peripherally targeted intervention aiming to reduce knee pain will reveal two groups. The non-responders group will be patients with predominantly centrally driven pain characteristics, who will show less analgesic response to the peripherally targeted intervention while the responders group will be patients with predominantly peripheral pain who will show a greater analgesic response to the peripherally targeted intervention. Both groups will respond similarly to placebo. However, this feasibility study is not intended to test the hypothesis of the main trial.

### METHODS AND ANALYSIS

#### Study design

The study will be a feasibility, double-blinded, placebo-controlled randomised parallel study in participants with radiographically defined knee OA and with self-reported chronic knee pain. The study design was guided by the recommendations of the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement extension to randomised pilot and feasibility trials. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines (online supplemental file A).

#### Study setting

This is a single-centre study. The study activities will be carried out at the Sir Peter Mansfield Imaging Centre, University of Nottingham.

#### Sample size

This is a feasibility study aiming to provide first proof of concept and descriptive statistics to power a future diagnostic trial. We aim to recruit 50 participants (25 to each group). This would be a large enough sample to assess the feasibility and inform a main trial based on statistical methodological papers providing recommendations about sample size requirements for feasibility and pilot studies.

#### Eligibility criteria

The inclusion criteria are; patients aged 45 years and older who have the capacity to give informed consent and have radiographically defined OA knee changes (Kellgren and Lawrence Grading System K/L>2/4) with knee pain, particularly self-reported knee pain at the most severely affected side measuring between 30 and 80 mm on a 100 mm Visual Analogue Scale (VAS) for rest, use or night pain and being able to perform the 6-minute walk test (6MWT). The VAS anchors are: 0 as ‘no pain’ and 100 as ‘the worst pain imaginable’.
The exclusion criteria are: patients having major medical, neurological and psychiatric comorbidities that would preclude completion of the study protocol. Patients who have a diagnosis of OA in any joint other than the knee with pain VAS≥30 mm, fibromyalgia, systemic or local knee infection, severe coagulopathy or taking anti-coagulant therapy, known hypersensitivity to bupivacaine, taking neuropathic pain medications for their OA-related pain such as strong opioid analgesics and antiepileptic drugs will also be excluded. Known contraindications for MRI are also exclusion criteria.

Recruitment
The trial flow is summarised in figure 1. Eligible participants will be recruited mainly through the secondary care pathway at the Trauma and Orthopaedic department in Nottingham University Hospitals (NUH) National Health Service (NHS) Trust. The clinical team directly involved in patient care will identify participants as part of their routine clinical review. In addition, there are other potential methods of patient recruitment to the UP-KNEE study, such as Primary Care pathways and participants who have previously participated in previous research in the Pain Centre Versus Arthritis and gave consent to be contacted again regarding future studies.

Informed, written consent will be obtained prior to any research activities (online supplemental file B). The participant will be given the opportunity to choose whether they consent via phone or at the appointment. Verbal consent will be taken in accordance with NUH verbal consenting guidance. Participants can withdraw from the study at any timepoint. In the event of their withdrawal, data already collected will be used, but no further data will be acquired.

Randomisation procedure and concealment of allocation
Eligible participants will be randomised in a 1:1 allocation ratio. An online computer service (SealedEnvelope.com) will be used for stratified randomisation to either intra-articular injection of bupivacaine or sodium chloride 0.9%. This facility generates codes that are concealed from the research team to either group. To mitigate against risk of allocation imbalance with respect to whether pain is predominantly centrally or peripherally driven, stratification will be based on the scores of the Central Aspects of Pain in the Knee (CAP-Knee) questionnaire, which will be sent to participants before the research visit. Participants will be randomised on a 1:1 allocation basis to either bupivacaine or placebo. To ensure blinding of the investigators to the participant’s group assignment, an authorised research nurse will prepare the allocated treatment. The randomisation schedule will be embedded by the research nurse in a secure password-protected folder to achieve allocation concealment.

Blinding
Investigators and participants will be blind to the treatment allocation. To reduce the risk of interpretation bias, investigators analysing the data will also be blinded to the treatment allocation, and any manual image analysis will be performed by an investigator blinded to clinical status.

Emergency unblinding will only be done if emergencies occur that can be directly linked to the study medication, where it is essential to know if the patient was actually given bupivacaine.

Experimental procedures
The study involves a single visit in which data will be collected. As per the study protocol (V.1.6, 26 January 2023), the interventions will include an assessment to check patients’ suitability to undergo intervention with a local anaesthetic (bupivacaine) or placebo (sodium chloride 0.9%) intra-articular knee injection. During the visit, all participants will be invited to undertake the following assessments: (1) complete health questionnaires; (2) undergo QST; (3) MRI scan of the knee and brain; (4) perform a 6MWT; and (5) participants will then receive an intra-articular injection of bupivacaine or placebo into the index knee. Assessments will be repeated post intra-articular injection apart from the MRI scan of the knee.

Online supplemental file C contains a detailed description of the study intervention, written in accordance with the Template for Intervention Description and Replication (TIDieR) checklist and guide.

The timings of the postinjection assessments were chosen based on the impact of the timing of bupivacaine administration on its analgesic effects. As the time to peak concentration is 43.4±23.1 min based on previous research using bupivacaine for peripheral analgesia,21 there will be a 20 min interval post injection to ensure sufficient time to demonstrate the full effect of local anaesthesia and for the postprocedural care. The post-injection procedures will then be completed between 20 and 60 min post injection.

Psychometric questionnaires
Questionnaires will be used to rate the pain severity and to evaluate psychosocial constructs. The questionnaires set include painDETECT,22 Pain Catastrophizing Scale,23 CAP-Knee questionnaire,24 Beck Depression Inventory,25 Measure of Intermittent and Constant Osteoarthritis Pain questionnaire,26 EuroQol 5 Dimension 5 Level (EQ-5DL) questionnaire,27 Oxford Knee Score,28 Pittsburgh Sleep Quality Index,29 Fatigue Severity Scale30 and the State-Trait Anxiety Inventory.31

At the end of the research visit, the participant will also be asked to fill in a custom-made questionnaire with open-ended questions intended to further investigate aspects of study feasibility and acceptability of the method.

6MWT pre and post injection of bupivacaine/placebo
The self-paced 6MWT is aimed to be the functional outcome measure as it can assess the submaximal level of functional capacity. Participants will be requested to undertake a paced walk and are also allowed to stop and...
**Figure 1** Overall trial flow. fMRI, functional MRI; GP, general practice; OA, osteoarthritis; PIS, participant information sheet; QMC, Queen's Medical Centre; QST, quantitative sensory testing; SPMIC, Sir Peter Mansfield Imaging Centre; TKR, total knee replacement.
rest during performing the test. Participants will be asked to rate the level of knee pain ‘pain this instant’ before and immediately after the test finishes using the 0–100 VAS. The walking course of the 6MWT will be 30 m in length with a mark every 3 m.

**Quantitative sensory testing**

QST is a psychophysical technique evaluating sensory response to standardised mechanical or thermal stimuli. The study will use static pain parameters; pressure pain detection threshold (PPT), and dynamic parameters; temporal summation of pain (TSP) and conditioned pain modulation (CPM). Several lines of evidence suggest that QST can be used to phenotype OA pain based on mechanisms. Enrolled patients will undergo the following QST measures: PPT, TSP and CPM, which will be performed according to a standardised methodology32–34 (online supplemental file D).

**Intra-articular knee joint injection with bupivacaine/placebo**

Bupivacaine or sodium chloride 0.9% will be administered via the intra-articular route by a member of the research team (a qualified medic) with appropriate competence in intra-articular injection and the recognition and management of the potential adverse effects. The injection will be carried out under aseptic conditions.

For intra-articular injection, the injected volume of either bupivacaine 0.25% (5 mL) or sodium chloride 0.9% (5 mL) will be the same for each participant. Bupivacaine was selected for the intra-articular injection to achieve analgesia because this was shown in previous studies to significantly reduce knee pain in participants with knee OA 1 hour after injection.12 13

**MRI of the knee before the injection**

The participants will also undergo a short structural MRI of the knee at 3 T in order to define synovitis, bone marrow lesions and other structural pathologies in the knee joint. MRI of the knee will be evaluated using the validated semiquantitative MRI Osteoarthritis Knee Score (MOAKS).35

**Brain imaging**

The participants will undergo a multimodal MRI scan of the brain at 3 T before and after the intra-articular injection. This study will use the functional MRI (fMRI) protocol from studies in pain imaging that can characterise spontaneous chronic pain.36–38

**Outcomes**

**Primary outcome measures**

1. The change in pain score using a 100 mm VAS during the 6MWT from baseline to 1 hour after intra-articular injection with bupivacaine or placebo.
2. The change in pain score using the VAS at rest from baseline to 1 hour after intra-articular injection with bupivacaine or placebo.

**Secondary outcome measures**

1. QST: the change scores of PPT, TSP and CPM from baseline to post intra-articular injection with bupivacaine or placebo.
2. fMRI of the brain: the change in brain network activity from baseline to post intra-articular injection with bupivacaine or placebo.
3. MOAKS35: the level of joint damage quantified by MOAKS and measured at baseline.
4. Feasibility assessment: the number and percentage of eligible participants who are recruited and randomised to the study from the date of recruitment opening until the date of recruitment closing, as well as protocol completion rates and missing data rates.
5. Feasibility assessment: evaluation of effective randomisation of participants to the study arms using a study-specific checklist and assessment of the randomisation protocol throughout the study.
6. Feasibility assessment: a study-specific questionnaire will be administered to participants to assess the acceptability of the study at the end of the research visit.

**Data management and auditing**

The collection, storage, processing and disclosure of personal information, data collection and management will comply with the requirements of the General Data Protection Regulation 2018. Handling of data will follow the policies and the procedures of the Sponsor (NUH NHS Trust) and the University of Nottingham. All personal data will be anonymised, and all further data analysis will be done without any reference to personal identifiable participant data.

The trial conduct will be monitored by the Sponsor (NUH NHS Trust).

**Statistical methods**

1. Considering the feasibility nature of the study, no formal hypothesis tests will be performed to statistically compare the two study arms and descriptive statistics will be presented. Appropriate parametric or non-parametric statistics will be used according to the data characteristics.
2. Summary statistics will be used to evaluate feasibility objectives such as the feasibility to recruit, timing measurements, to describe the sample and to inform the future main trial by providing power and sample size calculation. Participant acceptability feedback will be qualitatively synthesised using thematic analysis.
3. Primary and secondary outcomes will be descriptively summarised by group as follows:
   1. Correlations between the change of pain score and QST measurements at baseline and after intra-articular injection with bupivacaine or placebo.
   2. Correlations between the change of pain score and brain network activity at baseline and after intra-articular injection with bupivacaine or placebo using predefined seeds in the pain processing regions.
3. Correlations between the change of pain score and the level of joint damage quantified by MOAKS and measured at baseline.

4. Estimates of between-group effect will be reported as estimates with 95% CIs without p values.

5. In view of the exploratory nature of the study, missing data will not be imputed. The proportion of missing data for each outcome will be described.

6. Differences in effects will be reported descriptively for primary and secondary outcomes between the following subgroups:
   1. Based on the stratification variable according to CAP-Knee Questionnaire scores with respect to whether pain is predominantly centrally or peripherally driven.
   2. The patients will be divided into responders and non-responders based on a cut-off value of ≥17 mm reduction in VAS post injection.

**Safety and adverse events**

The study was deemed a low-risk study by the Sponsor (NUH NHS Trust). Adverse events will be recorded and reported according to the policies of the local Research Ethics Committee and NUH NHS Trust.46

**Patient and public involvement**

The study protocol and documents have been reshaped according to input received in two patient and public involvement (PPI) events via Pain Centre Versus Arthritis PPI advisory group. This advisory group was composed of people with OA who provided constructive feedback on the outcome measures and the study methods, which led to enhanced study design. The PPI will be maintained throughout the study and will help with dissemination of the study findings and outcomes to ensure a broader perspective.

**ETHICS AND DISSEMINATION**

The study has been approved by the Nottingham Research Ethics Committee 1 (REC Reference: 20/EM/0287). The study results will be disseminated through peer-reviewed journals and communicated at scientific meetings and conferences. The results will also be presented in relevant patient websites. Authorship eligibility will be based on the recommendations from the International Committee of Medical Journal Editors (ICMJE).

**PERSPECTIVES OF THE STUDY**

This feasibility randomised controlled trial will provide first proof of concept to a future main trial. The study has the scope to enhance the understanding of knee OA pain mechanisms and to pave the way for individualised treatment in knee OA.

**CURRENT TRIAL STATUS**

HRA approval has been obtained. Recruitment was initiated in late 2022.

**REFERENCES**


**Author affiliations**

1. Radiological Sciences, Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Nottingham, UK
2. Pain Centre Versus Arthritis, School of Medicine, University of Nottingham, Nottingham, UK
3. Sir Peter Mansfield Imaging Centre, School of Medicine, University of Nottingham, Nottingham, UK
4. Clinical Pharmacy Practice, School of Pharmacy, University of Nottingham, Nottingham, UK
5. School of Allied Health Professions, Keele University, Keele, UK
6. Academic Orthopaedics, Trauma and Sports Medicine, School of Medicine, University of Nottingham, Nottingham, UK
7. Academic Rheumatology, School of Medicine, University of Nottingham, Nottingham, UK

**Contributors**

BES conceived the study and designed the protocol with YZ, RK, DC, TK, DAW and DPA. YZ communicated with the Regulatory Authorities, initiated the study and wrote the first draft of the manuscript. All authors reviewed and approved this manuscript for submission.

**Funding**

This project is supported by Versus Arthritis (Grant reference number: 20777).

**Competing interests**

None declared.

**Patient and public involvement**

Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

**Patient consent for publication**

Not applicable.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Supplemental material**

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and any change is indicated. This does not affect the acceptability of articles that incorporate text licensed under other terms, provided the text is identified as non-BMJ and the BMJ reputation is not used inappropriately. BMJ does not warranty the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Supplemental material**

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**ORCID iD**

Yasmine Zedan http://orcid.org/0000-0002-6363-1374

**BMJ Open** first published as 10.1136/bmjopen-2023-072138 on 11 July 2023. Downloaded from http://bmjopen.bmj.com on October 23, 2023 by guest. Protected by copyright.


29 Smyth C. n.d. The Pittsburgh sleep quality index (PSQI). (0098-9134 (print)).


# SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

<table>
<thead>
<tr>
<th>Section/item</th>
<th>Item No</th>
<th>Description</th>
<th>Page and Line Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administrative information</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym</td>
<td>Page 1: Line 1-4</td>
</tr>
<tr>
<td>Trial registration</td>
<td>2a</td>
<td>Trial identifier and registry name. If not yet registered, name of intended registry</td>
<td>Page 2: Line 38</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>All items from the World Health Organization Trial Registration Data Set</td>
<td>N/A</td>
</tr>
<tr>
<td>Protocol version</td>
<td>3</td>
<td>Date and version identifier</td>
<td>Page 6: Line 193</td>
</tr>
<tr>
<td>Funding</td>
<td>4</td>
<td>Sources and types of financial, material, and other support</td>
<td>Page 10: Line 370</td>
</tr>
<tr>
<td>Roles and responsibilities</td>
<td>5a</td>
<td>Names, affiliations, and roles of protocol contributors</td>
<td>Page 10: Line 365-367</td>
</tr>
<tr>
<td></td>
<td>5b</td>
<td>Name and contact information for the trial sponsor</td>
<td>Page 9: Line 301</td>
</tr>
<tr>
<td></td>
<td>5c</td>
<td>Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities</td>
<td>Page 9: Line 300-303</td>
</tr>
<tr>
<td></td>
<td>5d</td>
<td>Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)</td>
<td>Page 9: Line 297-303</td>
</tr>
</tbody>
</table>

## Introduction

---

*BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s) BMJ Open doi: 10.1136/bmjopen-2023-072138.*
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Background and rationale</td>
<td>Page 3</td>
<td>Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention.</td>
</tr>
<tr>
<td>6b Explanation for choice of comparators</td>
<td>Page 3: Line 81-85</td>
<td></td>
</tr>
<tr>
<td>Objectives</td>
<td>Page 4: Line 90-112</td>
<td>Specific objectives or hypotheses.</td>
</tr>
<tr>
<td>Trial design</td>
<td>Page 4: Line 115-120</td>
<td>Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory).</td>
</tr>
<tr>
<td>Methods: Participants, interventions, and outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study setting</td>
<td>Page 4: Line 122-124</td>
<td>Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained.</td>
</tr>
<tr>
<td>Eligibility criteria</td>
<td>Page 5: Line 133-149</td>
<td>Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists).</td>
</tr>
<tr>
<td>Interventions</td>
<td>Page 6-8: Line 188-261</td>
<td>Interventions for each group with sufficient detail to allow replication, including how and when they will be administered.</td>
</tr>
<tr>
<td>11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)</td>
<td>Page 5: Line 164-166</td>
<td></td>
</tr>
<tr>
<td>11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)</td>
<td>Page 8: Line 282-292</td>
<td></td>
</tr>
<tr>
<td>11d Relevant concomitant care and interventions that are permitted or prohibited during the trial</td>
<td>Page 6: Line 207</td>
<td></td>
</tr>
</tbody>
</table>
Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended

Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)

Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations

Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions

Allocation concealment mechanism 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned

Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions
### Blinding (masking)

17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how

17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial

### Methods: Data collection, management, and analysis

#### Data collection methods

18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol

18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols

#### Data management

19 Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol

#### Statistical methods

20a Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol

20b Methods for any additional analyses (eg, subgroup and adjusted analyses)

20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)

### Methods: Monitoring
<table>
<thead>
<tr>
<th>Section</th>
<th>Item</th>
<th>Description</th>
<th>Page/Line</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data monitoring</td>
<td>21a</td>
<td>Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed</td>
<td>Page 9: Line 297-303</td>
</tr>
<tr>
<td></td>
<td>21b</td>
<td>Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial</td>
<td>N/A</td>
</tr>
<tr>
<td>Harms</td>
<td>22</td>
<td>Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct</td>
<td>Page 10: Line 335-339</td>
</tr>
<tr>
<td>Auditing</td>
<td>23</td>
<td>Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor</td>
<td>Page 9: Line 304-305</td>
</tr>
<tr>
<td>Ethics and dissemination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research ethics approval</td>
<td>24</td>
<td>Plans for seeking research ethics committee/institutional review board (REC/IRB) approval</td>
<td>Page 2: Line 32</td>
</tr>
<tr>
<td>Protocol amendments</td>
<td>25</td>
<td>Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)</td>
<td>Implied in page 9: Line 297-301 as the study will follow the standardised procedures and policies of the Sponsor</td>
</tr>
<tr>
<td>Consent or assent</td>
<td>26a</td>
<td>Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)</td>
<td>Page 5: Line 161-166</td>
</tr>
<tr>
<td></td>
<td>26b</td>
<td>Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable</td>
<td>N/A</td>
</tr>
<tr>
<td>Confidentiality</td>
<td>27</td>
<td>How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial</td>
<td>Page 9: Line 298-300</td>
</tr>
</tbody>
</table>
Declaration of interests 28 Financial and other competing interests for principal investigators for the overall trial and each study site  Page 11: Line 374-375

Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators  Page 9: Line 297-302

Ancillary and post-trial care 30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation  N/A

Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions  Page 10: Line 353-355

31b Authorship eligibility guidelines and any intended use of professional writers  Page 10: Line 355-357

31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code  N/A

Appendices

Informed consent materials 32 Model consent form and other related documentation given to participants and authorised surrogates  Supplementary B

Biological specimens 33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable  N/A

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported license.
Nottingham University Hospitals

Participant Consent Form

Version: 1.1 – Date: 04/01/2023 – IRAS number: 270642
Understanding Pain Mechanisms in Knee OA — UP-KNEE study

Full Title: Is there a difference in the analgesic response to intra-articular bupivacaine injection in people with knee osteoarthritis pain with or without central sensitisation?: a feasibility randomised controlled trial

Chief Investigator: Professor Brigitte Scammell (Nottingham University Hospitals NHS Trust)
Principal Investigator: Dr Yasmine Zedan

Participant Study ID: ................. Initials: ............... Participant initial each box

1. I confirm that I have read and understand the information sheet dated (version _____) and the additional information leaflet dated _______ (version _____) for the above study and have had the opportunity to ask questions.

2. I understand that my participation is voluntary and that I am free to withdraw at any time without my medical care or legal rights being affected.

3. I understand that my medical records may be looked at by authorised individuals from the Sponsor for the study, the research group and the UK Regulatory Authority in order to check that the study is being carried out correctly.

4. I understand that even if I withdraw from the above study, the data collected from me will be used in analysing the results of the trial.

5. I consent to the storage including electronic, of personal information for the purposes of this study. I understand that any information that could identify me will be kept strictly confidential and that no personal information will be included in the study report or other publication.

6. I understand that my participation in the study will involve having an injection of either a local anaesthetic (bupivacaine) or placebo (a mixture of salt and water) into my knee joint.

7. I understand that participation in the study will involve MRI scans of my brain and knee and an x-ray of my knee (if needed).

8. I agree that my GP, or any other doctor treating me, will be notified of my participation in this study.

9. I understand that should there be any abnormal findings on either the fMRI scans, knee MRI or x-rays taken as part of this study, I agree to my GP being contacted.

10. I agree to take part in the study.

11. I agree to being contacted regarding future research studies (OPTIONAL)

Name of the patient (Print) date Patient’s signature

Name of person receiving consent (Print) date Signature

Original to be retained and filed in the site file. 1 copy to patient, 1 copy to be filed in patient’s notes.

IRAS 270642 UP-KNEE Informed Consent Form Version 1.1, 04JAN2021
Supplementary C

Is there a difference in the analgesic response to intra-articular bupivacaine injection in people with knee osteoarthritis pain with or without central sensitisation?: a feasibility randomised controlled trial

Template for intervention description and replication (TIDieR) checklist

1. **BRIEF NAME:**
   Intra-articular knee injection with bupivacaine/placebo

2. **WHY:**
   There is a need for a better mechanistic understanding of individual factors affecting pain relief, consequently informing personalised treatment guidelines. The aim of this research is to conduct a feasibility study in order to provide a strategy for a future randomised clinical trial by comparing the effect of a peripherally targeted intervention (intra-articular bupivacaine injection) versus placebo in pre-surgical knee OA with and without signs of centrally mediated pain mechanisms. We have selected intra-articular injection of bupivacaine to achieve analgesia because this was shown to reduce knee pain in participants with knee OA one hour after injection.\(^2,3\)

3. **WHAT:**
   **Materials:**
   Bupivacaine is used in clinical practice (combined with corticosteroids) for pain relief. This study does not have the intention to treat. This is not a clinical trial of an IMP.

   **Description of bupivacaine (active drug):**
   Bupivacaine is a local anaesthetic agent with a slow onset of action of approximately 2-5 minutes after injection and its effects last longer between approximately 2-4 hours after wash out for single knee injection. Bupivacaine binds to the intracellular portion of sodium channels and blocks sodium influx into nerve cells, preventing depolarization and the generation and conduction of nerve impulses. Its chemical designation is 1-butyl-N-(2,6-dimethylphenyl) piperidine-2-carboxamide. The empirical formula is C\(_{18}\)H\(_{28}\)N\(_2\)O, which corresponds to a molecular mass of 288.43 g/mol. Its pharmaceutical form is in a white crystalline powder that is freely soluble in 95 per cent ethanol, soluble in water, and slightly soluble in chloroform or acetone.

   The substance for placebo is sodium chloride (5 ml, 9mg/ml, 0.9% solution for injection).

   **Procedures:** Bupivacaine/sodium chloride will be administered in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function. For intra-articular injection, the dosage of bupivacaine (5 ml, 0.25%w/v bupivacaine) and sodium chloride (5 ml, 0.9% solution for injection) will be the same for each participant.

4. **WHO PROVIDED:**
   Bupivacaine/sodium chloride will be administered by personnel experienced in their use, with training from the Nottingham University Hospitals NHS Trust, and have also been trained in advanced life support and anaphylaxis management.
5. **HOW:**
Bupivacaine/sodium chloride will be administered by the intra-articular route.

6. **WHERE:**
Bupivacaine/sodium chloride will be administered in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function under totally aseptic conditions.

7. **WHEN and HOW MUCH:**
The study involves a single visit which will include an assessment to check patients’ suitability to undergo intervention with bupivacaine/placebo intra-articular knee injection. During the visit, all participants will be invited to undertake the following assessments: 1) a suite of psychometric questionnaires; 2) Quantitative Sensory Testing; 3) MRI scan of the knee and brain; 4) a 6-Minute Walk Test; and 5) a single intra-articular injection of either bupivacaine (5 ml, 0.25%w/v bupivacaine) or sodium chloride (5 ml, 0.9% solution for injection) into the index knee. Assessments will be repeated post intra-articular injection apart from the knee MRI scan.

8. **TAILORING:**
N/A

9. **HOW WELL:**
**Planned:**
All clinicians who will deliver the intra-articular injection in this study have been trained in Nottingham University Hospitals NHS Trust, and have also been trained in advanced life support and anaphylaxis management. The clinicians will adhere to a standardised protocol of injection. Protocol completion rates will be collected as one of the study outcomes.

**References**
Supplementary D:

Quantitative Sensory Testing (QST) protocol:
This protocol follows standardised methodology described in previous studies.1–5

**Pressure Algometry**
To examine pressure pain thresholds (PPT), a handheld pressure algometer (Somedic AB, Sösdala, Sweden) will be used. Pressure will be increased by 30kPa/s until the participant perceives a change of the stimulus from a pressure sensation to pain sensation. The participant will then press a response button and the algometer probe will be immediately withdrawn. The PPT score in kPa is the pressure applied at the time the response button was pressed.

PPT will be recorded from the following sites:
1. Medial joint line of the index knee (the most painful knee): 2 cm proximal to superomedial patellar margin.
2. Lateral joint line of the index knee: 2 cm proximal to superolateral patellar margin.
3. The tibialis anterior muscle as a distant site to examine spreading sensitization.
4. the extensor carpi radialis longus (ECRL) muscle as a remote site to examine widespread hyperalgesia.

A practise test will be done on each site then PPTs will be recorded in triplicates which will then be averaged per site for further analysis.

**Cuff Pressure Algometry**
A cuff algometer (NociTech and Aalborg University, Denmark) comprised of two 13 cm single chamber tourniquet cuffs (VBM, Sulz, Germany) will use computer-controlled cuff pressure stimuli to assess pain sensitivity of the deep tissue. The device is connected to an air compressor and an electronic VAS rating system (Aalborg University) which is sampled at 10 Hz.

The cuff will be applied at the level of the ipsilateral gastrocnemius muscle and will be inflated at a rate of 1kPa/s until max pressure limit of 100 kPa. The participant will rate his pressure-induced pain severity continuously using the VAS rating system and will press a button to release the pressure. The cuff pain detection threshold (PDT) is the pressure value when the subject rated pain as 1 cm on the VAS rating system.

The cuff pain tolerance threshold (PTT) is the value of maximum pressure at the point the subject had to press the release button because of intolerable pain severity.

**Temporal Summation of Pain (TSP) by Cuff Algometry**
Ten consecutive cuff pressure stimulations comprised of 1-second stimulus with a 2-second inter-stimulus-interval with an intensity equal to the PTT score will be applied ipsilateral to the index knee. Participants will rate the pain severity continuously throughout the stimulation using the VAS slider and to not return the VAS slider to zero in between cuff stimulations. A constant pressure of 5 kPa is retained by the cuff in-between stimulations to ensure that fixed position of the cuff on the leg during the examination. The VAS score is recorded immediately after each individual cuff stimulus.

TSP score is calculated by subtracting the mean VAS score of the first to 4th cuff stimulations (VAS-I) from the mean VAS score of the 8th to 10th cuff stimulations (VAS-II).
**Conditioning Pain Modulation by Cuff Algometry**

A painful conditioning stimulus will be applied contralateral to the index knee using the cuff with an inflation pressure equals 70% of the participant’s cuff PTT. As a test stimulus, PDT will be simultaneously examined on the ipsilateral side using the second cuff. Conditioning pain modulation (CPM) will be calculated by subtracting the unconditioned PDT score from the conditioned PDT score.

**References**


